+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Immunodeficiency Virus Therapeutics Market - Global Forecast 2026-2032- Product Image
Human Immunodeficiency Virus Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Human Immunodeficiency Virus Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674546
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Immunodeficiency Virus Therapeutics Market is projected to reach USD 22.23 Billion in 2026. It is expected to continue growing at a CAGR of 4.71%, reaching USD 29.32 Billion by 2032.

Human immunodeficiency virus therapeutics remains a high-priority pharmaceutical segment shaped by lifelong antiretroviral therapy, rising demand for simplified regimens, and global treatment targets. UNAIDS reported 39.9 million people living with HIV in 2023, with 30.7 million receiving antiretroviral therapy, confirming a large and durable need for effective HIV drugs, adherence support, and resistance management.

The therapeutic landscape is anchored by integrase strand transfer inhibitor-based regimens, two-drug maintenance therapy, long-acting injectable HIV treatment, and salvage therapies for heavily treatment-experienced patients. Industry progress is increasingly linked to durable viral suppression, fewer drug interactions, improved tolerability, differentiated intellectual property, and broader access across high-burden and emerging healthcare systems.

Transformative Shifts in the HIV Therapeutics Landscape

The HIV therapeutics landscape is shifting from daily pill burden toward patient-centered, long-acting, and resistance-aware care. FDA- and EMA-approved long-acting cabotegravir plus rilpivirine has validated injectable maintenance therapy for virologically suppressed adults, while lenacapavir has expanded options for multidrug-resistant HIV through a twice-yearly capsid inhibitor approach.

Policy and procurement dynamics are also changing. WHO guidance favoring dolutegravir-based first-line regimens, growing adoption of differentiated service delivery, and expanding generic manufacturing have increased treatment coverage in low- and middle-income countries. At the same time, payer scrutiny in mature markets is pushing manufacturers to demonstrate adherence benefits, real-world durability, safety, and value versus lower-cost oral generics.

Cumulative Impact of Artificial Intelligence on HIV Therapeutics

Artificial intelligence is becoming a cumulative force across HIV therapeutics, not a standalone intervention. AI-enabled molecular modeling, viral sequence analysis, and trial design tools can support target identification, resistance prediction, and faster evaluation of combination therapies, especially where mutation patterns reduce response to standard antiretroviral therapy.

Commercial and clinical operations are also benefiting from AI. Predictive analytics can identify adherence risk, care gaps, and potential loss to follow-up, which is critical because sustained viral suppression prevents disease progression and transmission. However, AI adoption must be governed by validated datasets, privacy safeguards, bias monitoring, and clinical oversight to ensure tools improve outcomes rather than widen inequities.

Key Regional Insights for HIV Therapeutics

Asia-Pacific combines large treatment demand with uneven access, with China, India, Japan, Australia, and South Korea representing distinct reimbursement, manufacturing, and innovation profiles. India remains central to global generic antiretroviral supply and access programs, while Japan, Australia, and South Korea emphasize high-quality specialty care, rapid diagnosis, and access to novel HIV regimens. China is expanding treatment coverage and domestic pharmaceutical innovation, supported by public health initiatives and increasing clinical research activity.

North America remains a premium innovation region led by the United States and Canada, where rapid regulatory pathways, specialty pharmacy infrastructure, clinical trial density, and uptake of branded long-acting therapies support high-value therapeutic adoption. Europe benefits from centralized and national health technology assessment processes, broad treatment coverage, and strong clinical guideline alignment, though pricing discipline and comparative effectiveness reviews shape launch sequencing and reimbursement access.

Latin America, the Middle East, and Africa show rising demand tied to public-sector procurement, donor-supported programs, and national HIV strategies. Brazil has a mature public HIV treatment program and established domestic policy commitment to antiretroviral access, while GCC countries are expanding specialty care through public funding and centralized purchasing. Africa remains the global epidemiological center of HIV, with UNAIDS reporting that eastern and southern Africa carry the highest burden, making affordability, supply security, differentiated service delivery, and regimen simplification essential to treatment continuity.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly important for HIV therapeutics as governments expand testing, treatment initiation, and community-based service models, though access varies by income level, stigma reduction, and health infrastructure. The GCC is characterized by smaller reported patient populations, higher specialty-care capacity, and demand for innovative HIV therapies supported by public funding, centralized purchasing, and hospital-led treatment pathways.

The European Union and G7 remain influential because they shape HIV clinical standards, pricing benchmarks, pharmacovigilance expectations, health technology assessment requirements, and intellectual property strategies. NATO membership does not directly determine HIV demand, but overlapping high-income health systems often prioritize medicine security, supply-chain resilience, emergency preparedness, and continuity of care for chronic infectious diseases.

BRICS countries represent a strategic mix of scale, manufacturing capability, and epidemiological need. Brazil, India, China, Russia, and South Africa influence generic availability, public procurement, local production, clinical access negotiations, and national HIV program design, making the group central to long-term HIV treatment affordability, supply diversification, and patient access in both domestic and export-oriented markets.

Key Country Insights for Priority HIV Therapeutics Markets

The United States leads in branded HIV therapeutics, clinical trials, guideline adoption, and rapid uptake of long-acting regimens, supported by established specialty pharmacy channels and federal HIV initiatives. Canada combines universal health coverage with provincial and territorial formulary decision-making, creating structured but regionally varied access. Mexico and Brazil are driven by public-sector treatment programs, with Brazil recognized for longstanding free antiretroviral access through its national health system and continued use of public procurement to support HIV care.

The United Kingdom, Germany, France, Italy, and Spain have mature treatment networks, high viral suppression goals, routine guideline-based care, and rigorous reimbursement evaluation. Germany and France are key early-access and clinical adoption markets, while the United Kingdom emphasizes national guideline alignment and centralized health technology assessment. Italy and Spain maintain strong specialist HIV care networks. Russia faces substantial treatment need and distinct procurement dynamics, while China is expanding domestic innovation and treatment coverage. India remains pivotal as a global supplier of generic antiretroviral medicines and a major contributor to affordable HIV treatment access.

Japan, Australia, and South Korea represent advanced Asia-Pacific HIV therapeutics markets with strong clinical infrastructure, aging treated populations, and demand for therapies with favorable safety, interaction, renal, bone, metabolic, and adherence profiles. Australia also benefits from robust public health systems and prevention-oriented HIV policy, while South Korea and Japan continue to prioritize high-quality specialty care and access to clinically differentiated regimens.

Actionable Recommendations for HIV Therapeutics Leaders

Industry leaders should prioritize differentiated regimens that improve adherence, reduce resistance risk, and address unmet needs in treatment-experienced populations. Investment should focus on long-acting delivery, novel mechanisms, pediatric and adolescent-friendly formulations, and combinations that lower pill burden while preserving high barriers to resistance.

Commercial strategy must align innovation with access. Manufacturers should support voluntary licensing, regional manufacturing partnerships, pharmacovigilance capacity, and real-world evidence programs that demonstrate viral suppression, persistence, safety, and quality-of-life benefits. Payers and providers should integrate adherence analytics, community-based delivery, stigma-reduction initiatives, and resistance surveillance to maximize treatment impact.

Research Methodology for Evidence-Based HIV Therapeutics Analysis

This executive summary is grounded in secondary research from authoritative public health and regulatory sources, including UNAIDS, WHO, CDC, FDA, EMA, national HIV treatment guidelines, peer-reviewed clinical literature, and public procurement and reimbursement information. Market interpretation emphasizes validated epidemiology, approved therapeutic classes, guideline-supported care pathways, documented access trends, and observable regulatory milestones.

The analysis applies triangulation across disease burden, treatment coverage, regulatory approvals, clinical adoption, payer behavior, health-system capacity, and regional access mechanisms. No unsupported market-size, market-share, or forecasting claims are used; conclusions are based on verified evidence, approved products, published guidance, and consistent signals from public health programs and pharmaceutical activity.

Conclusion: The Future of HIV Therapeutics

Human immunodeficiency virus therapeutics remains a resilient, innovation-led field with significant public health importance. The core demand driver is clear: millions of people require lifelong therapy, and sustained viral suppression depends on access to potent, tolerable, convenient, and affordable antiretroviral options.

Future competitiveness will be defined by long-acting HIV treatment, resistance solutions, equitable access, AI-supported care optimization, and credible real-world outcomes. Organizations that combine scientific differentiation with affordability, supply reliability, and delivery innovation will be best positioned to support global HIV control objectives and create durable therapeutic value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Human Immunodeficiency Virus Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Entry Inhibitors
7.2.1. Enfuvirtide
7.2.2. Maraviroc
7.3. Integrase Strand Transfer Inhibitors
7.3.1. Bictegravir
7.3.2. Dolutegravir
7.3.3. Elvitegravir
7.3.4. Raltegravir
7.4. Non-Nucleoside Reverse Transcriptase Inhibitors
7.4.1. Efavirenz
7.4.2. Etravirine
7.4.3. Nevirapine
7.4.4. Rilpivirine
7.5. Nucleoside Reverse Transcriptase Inhibitors
7.5.1. Abacavir
7.5.2. Emtricitabine
7.5.3. Lamivudine
7.5.4. Tenofovir
7.5.5. Zidovudine
7.6. Protease Inhibitors
7.6.1. Atazanavir
7.6.2. Darunavir
7.6.3. Fosamprenavir
7.6.4. Lopinavir
8. Human Immunodeficiency Virus Therapeutics Market, by Therapy Line
8.1. Introduction
8.2. Combination Therapy
8.2.1. Single Tablet Regimen
8.2.2. Multi Tablet Regimen
8.3. Monotherapy
8.4. Highly Active Antiretroviral Therapy
8.4.1. First-Line Therapy
8.4.2. Second-Line Therapy
8.5. Pre-Exposure Prophylaxis
8.6. Post-Exposure Prophylaxis
9. Human Immunodeficiency Virus Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intramuscular
9.2.2. Subcutaneous
9.2.3. Intravenous
9.3. Oral
9.3.1. Tablets
9.3.2. Capsules
9.3.3. Solutions
9.4. Topical
10. Human Immunodeficiency Virus Therapeutics Market, by Patient Type
10.1. Introduction
10.2. Adult
10.3. Pediatric
10.4. Geriatric
11. Human Immunodeficiency Virus Therapeutics Market, by Virus Type
11.1. Introduction
11.2. HIV-1
11.3. HIV-2
12. Human Immunodeficiency Virus Therapeutics Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Homecare Settings
12.4. Specialty HIV Clinics
12.5. Research Institutes
13. Human Immunodeficiency Virus Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Human Immunodeficiency Virus Therapeutics Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Human Immunodeficiency Virus Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Human Immunodeficiency Virus Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc
18.2. Aspen Pharmacare Holdings Limited
18.3. Aurobindo Pharma Limited
18.4. Boehringer Ingelheim International GmbH
18.5. Bristol-Myers Squibb Company
18.6. Cipla Limited
18.7. CytoDyn Inc
18.8. Dr Reddy's Laboratories Limited
18.9. Emcure Pharmaceuticals Limited
18.10. F Hoffmann-La Roche AG
18.11. Gilead Sciences Inc
18.12. GlaxoSmithKline plc
18.13. Glenmark Pharmaceuticals Limited
18.14. Hetero Labs Limited
18.15. Johnson & Johnson Services Inc
18.16. Lupin Limited
18.17. Macleods Pharmaceuticals Limited
18.18. Merck & Co Inc
18.19. Pfizer Inc
18.20. Strides Pharma Science Limited
18.21. Sun Pharmaceutical Industries Limited
18.22. TaiMed Biologics Inc
18.23. Teva Pharmaceutical Industries Ltd
18.24. Theratechnologies Inc
18.25. Viatris Inc
18.26. ViiV Healthcare Limited
18.27. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ENFUVIRTIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ENFUVIRTIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ENFUVIRTIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MARAVIROC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MARAVIROC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MARAVIROC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BICTEGRAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BICTEGRAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BICTEGRAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ELVITEGRAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ELVITEGRAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ELVITEGRAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL RALTEGRAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL RALTEGRAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL RALTEGRAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL EFAVIRENZ MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL EFAVIRENZ MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL EFAVIRENZ MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ETRAVIRINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ETRAVIRINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ETRAVIRINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL NEVIRAPINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL NEVIRAPINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL NEVIRAPINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL RILPIVIRINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL RILPIVIRINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL RILPIVIRINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ABACAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ABACAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ABACAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL EMTRICITABINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL EMTRICITABINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL EMTRICITABINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL LAMIVUDINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL LAMIVUDINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL LAMIVUDINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TENOFOVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TENOFOVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TENOFOVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ZIDOVUDINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ZIDOVUDINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ZIDOVUDINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ATAZANAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ATAZANAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ATAZANAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL DARUNAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL DARUNAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL DARUNAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL LOPINAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL LOPINAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL LOPINAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SINGLE TABLET REGIMEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SINGLE TABLET REGIMEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SINGLE TABLET REGIMEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL MULTI TABLET REGIMEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL MULTI TABLET REGIMEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL MULTI TABLET REGIMEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL POST-EXPOSURE PROPHYLAXIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL POST-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL POST-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL SOLUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL SOLUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL HIV-1 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL HIV-1 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL HIV-1 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL HIV-2 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL HIV-2 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL HIV-2 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL SPECIALTY HIV CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL SPECIALTY HIV CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL SPECIALTY HIV CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2017-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2017-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 204. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 205. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 210. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 211. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 212. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 213. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 214. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 215. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2017-2032 (USD MILLION)
TABLE 216. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2017-2032 (USD MILLION)
TABLE 217. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 219. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 220. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 221. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 222. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 224. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 225. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 226. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 227. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 228. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 229. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 230. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 231. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 232. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2017-2032 (USD MILLION)
TABLE 233. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2017-2032 (USD MILLION)
TABLE 234. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 235. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 236. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 237. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 238. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 239. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 240. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 241. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 242. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 243. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 244. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 245. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 246. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 249. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2017-2032 (USD MILLION)
TABLE 250. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2017-2032 (USD MILLION)
TABLE 251. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 253. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 254. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 255. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 256. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 258. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 259. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 260. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 261. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 262. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 263. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 264. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 265. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 266. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2017-2032 (USD MILLION)
TABLE 267. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2017-2032 (USD MILLION)
TABLE 268. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 270. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 271. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 272. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 273. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 275. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 276. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 277. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 278. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 279. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 280. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 281. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 282. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 283. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 284. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2017-2032 (USD MILLION)
TABLE 285. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2017-2032 (USD MILLION)
TABLE 286. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 288. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 289. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 290. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 291. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 292. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 293. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 294. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 295. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 296. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 297. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 298. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 299. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 300. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 301. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2017-2032 (USD MILLION)
TABLE 302. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2017-2032 (USD MILLION)
TABLE 303. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 304. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 305. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 306. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 307. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 308. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 310. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 311. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2017-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2017-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 321. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TA

Companies Mentioned

  • AbbVie Inc
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • CytoDyn Inc
  • Dr Reddy's Laboratories Limited
  • Emcure Pharmaceuticals Limited
  • F Hoffmann-La Roche AG
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hetero Labs Limited
  • Johnson & Johnson Services Inc
  • Lupin Limited
  • Macleods Pharmaceuticals Limited
  • Merck & Co Inc
  • Pfizer Inc
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Limited
  • TaiMed Biologics Inc
  • Teva Pharmaceutical Industries Ltd
  • Theratechnologies Inc
  • Viatris Inc
  • ViiV Healthcare Limited
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 22.23 Billion
Forecasted Market Value ( USD ) by 2032 $ 29.32 Billion
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Human Immunodeficiency Virus Therapeutics Market Report 2026 - Product Image

Human Immunodeficiency Virus Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Zika Virus Therapeutics - Global Strategic Business Report - Product Image

Zika Virus Therapeutics - Global Strategic Business Report

  • Report
  • 136 Pages
  • Global
From
Hepatitis C Virus: Epidemiology Report and Forecast to 2035 - Product Image

Hepatitis C Virus: Epidemiology Report and Forecast to 2035

  • Report
  • 108 Pages
  • Global
From
Zika Virus Therapeutics Market Report 2026 - Product Image

Zika Virus Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Respiratory Syncytial Virus Epidemiology Forecast 2026-2035 - Product Image

Respiratory Syncytial Virus Epidemiology Forecast 2026-2035

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.